(Company Registration Number: 196900437M) (Incorporated in the Republic of Singapore)

Unaudited First Quarter Financial Results for the Period Ended 31 March 2015

1(a) An income statement (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.

		Group	
	Period Ended 31 March		
	2015	2014	+ / (-)
	S\$'000	S\$'000	%
Revenue	45,552	38,395	18.6
Cost of sales	(18,005)	(15,418)	16.8
Gross profit	27,547	22,977	19.9
Other income	1,283	1,013	26.7
Distribution and marketing expenses	(10,254)	(9,056)	13.2
General and administrative expenses	(2,493)	(2,497)	(0.2)
Finance expenses	(127)	(75)	69.3
Profit from operations	15,956	12,362	29.1
Share of results of associated companies and gain on dilution of investment in associated company (net)	246	2,450	(90.0)
Profit before taxation	16,202	14,812	9.4
Taxation	(2,747)	(2,646)	3.8
Profit for the period, net of tax	13,455	12,166	10.6

A consolidated statement of comprehensive income for the quarter ended 31 March 2015:

		Group	
	Period	d Ended 31 March	
	2015	2014	+ / (-)
	S\$'000	S\$'000	%
Profit for the period, net of tax	13,455	12,166	10.6
Other comprehensive income, after tax, that may be reclassified subsequently to profit or loss:			
Fair value (losses)/gains on available-for-sale financial assets (net)	(65,273)	40,036	(263.0)
Currency translation differences on consolidation of foreign entities (net)	9,104	1,511	502.5
Other comprehensive (expense)/income for the period, net of tax	(56,169)	41,547	(235.2)
Total comprehensive (expense)/income for the period	(42,714)	53,713	(179.5)

N/M - not meaningful

Note:

As the 14.39% (Q1 2014: 14.28%) owned associate, Hua Han Bio-Pharmaceutical Holdings Limited ("HHBP") is not required to report quarterly results and is restricted by Hong Kong listing rules from releasing its results only to the Group, the above figures have not included the results of HHBP for the quarters ended 31 March 2015 and 2014.



1(a) Notes to the Income Statement

I(a) Notes to the income Statement		Group	
	Period	Ended 31 Ma	arch
	2015	2014	+ / (-)
	S\$'000	S\$'000	%
(i) Other income			
Investment income	184	236	(22.0)
Interest income	511	258	98.1
Miscellaneous income	588	519	13.3
	1,283	1,013	26.7
(ii) The following were charged/(credited)			
to the income statement :	407	75	60.2
Interest on borrowings	127	75 4 460	69.3 15.0
Depreciation of property, plant and equipment	1,334	1,160 235	
Loss on disposal and write-off of property, plant and equipment Allowance for impairment of receivables	16 8	235 -	(93.2) N/M
Inventories written down	o 27	- 21	28.6
Foreign exchange gain, net			26.0 N/M
Prior years' overprovision of current taxation	(79)	(3) (13)	(576.9)
·	(88)	(13)	179.5
Prior years' underprovision of deferred taxation	123		179.5
(iii) Segmental results Revenue			
Healthcare	38,621	29,947	29.0
Leisure	2,987	4,180	(28.5)
Property	2,987 3,944	4,160	(7.6)
Floperty	3,944	4,200	(7.0)
	45,552	38,395	18.6
Profit/(loss) from operations			
Healthcare	13,543	8,827	53.4
Leisure	(143)	697	(120.5)
Property	2,988	3,273	(8.7)
Investments	542	387	40.1
Unallocated expenses	(974)	(822)	18.5
	15,956	12,362	29.1



1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.

	Group		Company	
	31/03/15	31/12/14	31/03/15	31/12/14
	S\$'000	S\$'000	S\$'000	S\$'000
ASSETS				
Non august accets				
Non-current assets Property, plant and equipment	33,097	33,187	_	
Investment properties	215,256	225,249	_	_
Investment in subsidiaries	213,230	225,245	381,957	381,957
Investment in associated companies	142,081	137,690	2,895	2,895
Available-for-sale financial assets	1,801,591	1,842,662	330	330
Deferred income tax assets	267	263	-	-
Intangible assets	11,116	11,116	-	-
3	2,203,408	2,250,167	385,182	385,182
Current assets		· · · ·	•	
Available-for-sale financial assets	442,439	468,830	-	-
Inventories	9,443	10,720	-	-
Trade and other receivables	29,615	19,911	121,876	121,464
Cash and bank balances	237,638	224,666	212,774	194,270
	719,135	724,127	334,650	315,734
Investment property classified as held-for-sale	10,078	-		-
	729,213	724,127	334,650	315,734
Total assets	2,932,621	2,974,294	719,832	700,916
LIABILITIES				
Current liabilities				
Trade and other payables	40,494	39,066	85,349	72,286
Current income tax liabilities	8,802	7,587	362	283
Borrowings	58,659	56,332	58,659	56,332
	107,955	102,985	144,370	128,901
Non-current liabilities	E0 4E4	62.044		
Deferred income tax liabilities	59,451 59,451	63,844 63,844	-	<u>-</u>
	39,431	03,044		
Total liabilities	167,406	166,829	144,370	128,901
NET ASSETS	2,765,215	2,807,465	575,462	572,015
EQUITY		_		_
Equity attributable to equity holders				
of the Company				
Share capital	249,102	248,722	249,102	248,722
Retained profits	900,626	887,171	322,745	319,762
Other reserves	1,615,487	1,671,572	3,615	3,531
Total equity	2,765,215	2,807,465	575,462	572,015



1(b)(ii) Aggregate amount of group's borrowings and debt securities.

Amount repayable in one year or less, or on demand

As at 31/03/15		As at 31/12/14	
Secured	Unsecured	Secured	Unsecured
S\$'000	S\$'000	S\$'000	S\$'000
58,659	-	56,332	-

Amount repayable after one year

As at 3	As at 31/03/15		1/12/14
Secured	Unsecured	Secured Unsecur	
S\$'000	S\$'000	S\$'000	S\$'000
-	-	-	-

Details of any collateral

The Group has provided certain investment properties, available-for-sale financial assets and fixed deposits to secure its borrowings and credit facilities.



1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.

	Group		
	Period Ended 3	31 March	
	2015	2014	
	S\$'000	S\$'000	
Cash flows from operating activities:			
Profit before tax	16,202	14,812	
Adjustments for:			
Share of results and dilution adjustments of associated companies	(246)	(2,450)	
Depreciation of property, plant and equipment	1,334	1,160	
Finance expenses	127	75	
Expensing of share options	84	67	
Inventories written down	27	21	
Loss on disposal and write-off of property, plant and equipment	16	235	
Allowance for impairment of receivables	8	-	
Interest income	(511)	(258)	
Investment income	(184)	(236)	
Currency translation gains	(288)	(127)	
Operating profit before working capital changes	16,569	13,299	
Decrease in inventories	1,250	162	
Decrease/(increase) in trade and other payables	1,537	(1,999)	
Increase in trade and other receivables	(8,679)	(2,657)	
Cash generated from operations	10,677	8,805	
Investment income received	120	182	
Interest income received	69	211	
Net taxation paid	(2,069)	(713)	
Net cash provided by operating activities	8,797	8,485	
Cash flows from investing activities:			
Dividends from an associated company	3,669	4,960	
Purchase of property, plant and equipment	(241)	(993)	
Improvements to investment properties	(110)	-	
Proceeds from sale of property, plant and equipment	-	2	
Purchase of available-for-sale financial assets	-	(33,853)	
Net cash provided by/(used in) investing activities	3,318	(29,884)	
Cash flows from financing activities:			
Proceeds from issue of share capital	380	583	
Bank deposits pledged	10	(1)	
Interest expense paid	(127)	(69)	
Proceeds from borrowings	-	33,856	
Net cash provided by financing activities	263	34,369	
Net increase in cash and cash equivalents	12,378	12,970	
Cash and cash equivalents at beginning of the financial year	223,061	208,606	
Effects of currency translation on cash and cash equivalents	604	152	
Cash and cash equivalents at end of the period	236,043	221,728	
Cash and cash equivalents comprised the following:			
Cash and bank balances	237,638	223,390	
Less: Bank deposits pledged for banker's guarantee	(1,595)	(1,662)	
	236,043	221,728	
	•		



1(d) (i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.

				Foreign Currency		
	Share Capital	Fair Value Reserve	Other Reserve	Translation Reserve	Retained Profits	Total Equity
	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
The Group						
2015						
Balance at 1 January 2015	248,722	1,648,605	26,046	(3,079)	887,171	2,807,465
Issue of share capital	380	-	-	-	-	380
Expensing of share options	-	-	84	-	-	84
Total comprehensive (expense)/income for the period	-	(65,273)	-	9,104	13,455	(42,714)
Balance at 31 March 2015	249,102	1,583,332	26,130	6,025	900,626	2,765,215
2014						
Balance at 1 January 2014	246,848	1,368,797	23,752	(6,858)	812,182	2,444,721
Issue of share capital	583	-	-	-	-	583
Expensing of share options	-	-	67	-	-	67
Total comprehensive income for the period	-	40,036	-	1,511	12,166	53,713
Balance at 31 March 2014	247,431	1,408,833	23,819	(5,347)	824,348	2,499,084



1(d) (i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.

	Share Capital \$'000	Fair Value Reserve \$'000	Other Reserve \$'000	Retained Profits \$'000	Total Equity \$'000
The Company					
2015					
Balance at 1 January 2015	248,722	76	3,455	319,762	572,015
Issue of share capital	380	-	-	-	380
Expensing of share options	-	-	84	-	84
Total comprehensive income for the period	-	-	-	2,983	2,983
Balance at 31 March 2015	249,102	76	3,539	322,745	575,462
2014					
Balance at 1 January 2014	246,848	103	3,150	266,219	516,320
Issue of share capital	583	-	-	-	583
Expensing of share options	-	-	67	-	67
Total comprehensive income for the period	-	-	-	4,578	4,578
Balance at 31 March 2014	247,431	103	3,217	270,797	521,548



1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State also the number of shares that may be issued on conversion of all the outstanding convertibles as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

Since 31 December 2014, 62,000 shares were issued pursuant to the exercise of share options.

544,000 share options were granted at \$8.58 per ordinary share on 3 March 2015, of which 536,000 share options were accepted. During the period, 1,000 share options were cancelled.

As at 31 March 2015, unissued shares under the share option scheme of the Company were as follows:

	31/03/15	31/12/14
The Haw Par Corporation Group 2002 Share Option Scheme	1,476,000	1,003,000
	1,476,000	1,003,000

1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

	31/03/15	31/12/14
Total number of issued shares	219,024,173	218,962,173

1(d)(iv) A statement showing all sales, transfers, disposal, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

Not applicable.

2. Whether the figures have been audited, or reviewed and in accordance with which auditing standard or practice.

The figures as shown in the announcement have not been audited nor reviewed by the Company's auditor.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of a matter).

Not applicable.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.

These financial results have been prepared based on accounting policies and methods of computation consistent with those adopted in the most recently audited annual financial statements for the year ended 31 December 2014, except as stated in Note 5.



5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.

The Group adopted a number of new standards, amendments to standards and interpretations that are effective for annual periods beginning on or after 1 January 2015. The adoption of new standards, amendments to standards and interpretations did not result in any significant impact on the financial statements of the Group.

6. Earnings per ordinary share of the group for the current period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

	Grou	Group		
	Period Ended 31 March			
	2015	2014		
Earnings per ordinary share: (a) Based on the weighted average number of ordinary shares on issue	6.1 cts	5.6 cts		
(b) On a fully diluted basis	6.1 cts	5.6 cts		

- 7. Net asset value (for the issuer and group) per ordinary share based on the issued share capital of the issuer at the end of the:-
 - (a) current financial period reported on; and
 - (b) immediately preceding financial year.

	Group		Company	
	31/03/15	31/12/14	31/03/15	31/12/14
Net asset value per ordinary share (S\$)	12.63	12.82	2.63	2.61



- 8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:-
 - (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and
 - (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.

Income statement and statement of comprehensive income (1Q2015 vs 1Q2014)

Group revenue increased 18.6% from \$38.4m to \$45.6m mainly from Healthcare. Earnings increased 10.6% to \$13.5m mainly due to higher profit from operations, partially reduced by an absence of gain on dilution of investment in an associated company.

Healthcare's revenue of \$38.6m increased by 29% compared to 1Q2014 due to increase in sales from key markets. Lower cost of raw materials and more favorable exchange rates improved margins, thereby increasing operating profit by 53.4% to \$13.5m. Leisure's revenue decreased 28.5% from lower visitorship at both Underwater World Singapore and Pattaya. As a result, Leisure suffered a loss of \$143k due to weaker tourist arrivals and competition from newer attractions. Revenue from Property of \$3.9m decreased 7.6% compared to 1Q2014 due to lower occupancy rates. Property's profit of \$3.0m decreased 8.7%.

Other income increased 26.7% mainly from higher interest income.

Distribution and marketing expenses increased 13.2% mainly from increase in promotion and advertising expenses in Healthcare.

Finance expenses increased \$52k or 69.3% due to increase in borrowings compared to the corresponding prior period.

Contribution from associated companies decreased \$2.2m due to gain on dilution of investment in associated company recorded in the corresponding prior period.

The Group recorded net fair value losses of \$65.3m on available-for-sale financial assets as a result of lower market prices of quoted equity investments as at 31 March 2015.

Statements of financial position (31 March 2015 vs 31 December 2014)

Inventories decreased 12% to \$9.4m at 1Q2015 mainly due to timing of purchase of raw materials and shipments of finished goods.

The Group has reclassified one of its investment properties valued at \$10.1m to property held-for-sale. The property is available for immediate sale in its present condition and its sale is highly probable.

Trade and other receivables increased \$9.7m or 48.7% mainly due to increase in sales from Healthcare.

Current income tax liabilities increased \$1.2m or 16% during the quarter due to higher tax provision and timing differences of tax payment to various tax authorities.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

No forecast or prospect statement was made previously in respect of 1Q 2015 results.



10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

Improving standards of living, particularly in Asia, and growth in tourist traffic globally will continue to benefit Healthcare, albeit in an even more challenging environment.

Leisure could be further affected by the overall weakness in the Singapore and Pattaya tourism sectors and competition from newer attractions.

- 11. If a decision regarding dividend has been made: -
- (a) Whether an interim (final) ordinary dividend has been declared (recommended); and No

(b) (i) Amount per share:

- (ii) Previous corresponding period:
- (c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of the shareholders, this must be stated.)

Not applicable.

(d) The date the dividend is payable

Not applicable.

(e) The date on which Registrable Transfers received by the company (up to 5:00pm) will be registered before entitlements to the dividend are determined.

Not applicable.

12. If no dividend has been declared/recommended, a statement to that effect.

No dividend is declared by the Company for the quarter ended 31 March 2015.

13. If the Group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Group does not have any general mandate from shareholders pursuant to Rule 920.

14. Negative confirmation pursuant to Rule 705 (5) of the Listing Manual

CONFIRMATION BY THE BOARD

The Board of Directors hereby confirm that, to the best of its knowledge, nothing has come to its attention which may render the unaudited financial results of the Group for the guarter ended 31 March 2015 to be false or misleading.

BY ORDER OF THE BOARD HAW PAR CORPORATION LIMITED

Zann Lim Company Secretary 14 May 2015